No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Firebrick Pharma Obtains COVID-19 Patent for Nasodine in Mexico
Australian Shares Flat as CPI Slows in August; Sigma Healthcare Hits New 52-Week High After H1 Results
Firebrick Pharma Opens Share Purchase Plan; Shares Fall 4%
ASX Small-Cap Stocks to Watch
Firebrick Pharma Ltd: Appendix 4E and Annual Report 30 June 2024
Firebrick Pharma Eyes Nasodine Launch in the Philippines